Midatech Pharma US Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Midatech Pharma US Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0499
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. It is a subsidiary of Midatech Pharma Plc. The company’s product portfolio includes Gelclair, a treatment for oral mucositis; Zuplenz, a treatment for the prevention of nausea and vomiting in adult patients and Oravig, for the treatment of oral thrush. The company collaborates with pharmaceutical companies such as Mission Pharmacal to commercialize its product cancer supportive care products. It distributes its products through retail pharmacies, mail order pharmacies, and long-term care facilities in the US. Midatech Pharma is headquartered in Raleigh, North Carolina, the US.

Midatech Pharma US Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Midatech Pharma US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 11
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 12
DARA BioSciences Enters into Commercialization Agreement with Onxeo 13
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 14
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 15
Licensing Agreements 16
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 16
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 17
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 18
Equity Offering 19
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 19
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 21
Dara BioSciences Raises USD6 Million in Private Placement Of Shares 22
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 23
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 24
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 25
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 26
DARA BioSciences Completes Public Offering Of Units For US$10 Million 27
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 29
Acquisition 31
Midatech Pharma Acquires Dara BioSciences 31
DARA BioSciences Acquires Oncogenerix 33
Midatech Pharma US Inc – Key Competitors 34
Midatech Pharma US Inc – Key Employees 35
Midatech Pharma US Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Feb 28, 2018: Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Key Facts 2
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Midatech Pharma US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Midatech Pharma US Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 11
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 12
DARA BioSciences Enters into Commercialization Agreement with Onxeo 13
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 14
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 15
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 16
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 17
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 18
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 19
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 21
Dara BioSciences Raises USD6 Million in Private Placement Of Shares 22
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 23
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 24
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 25
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 26
DARA BioSciences Completes Public Offering Of Units For US$10 Million 27
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 29
Midatech Pharma Acquires Dara BioSciences 31
DARA BioSciences Acquires Oncogenerix 33
Midatech Pharma US Inc, Key Competitors 34
Midatech Pharma US Inc, Key Employees 35
Midatech Pharma US Inc, Subsidiaries 36

List of Figures
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Midatech Pharma US Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Penn Virginia Corp (PVAC):石油・ガス:M&Aディール及び事業提携情報
    Summary Penn Virginia Corp (Penn Virginia) is an independent oil and gas company. It explores, develops, and produces crude oil, Natural gas liquids (NGL), and natural gas. The company’s operations consist primarily of drilling unconventional horizontal development wells and operating producing well …
  • Wirtgen GmbH:企業の戦略・SWOT・財務情報
    Wirtgen GmbH - Strategy, SWOT and Corporate Finance Report Summary Wirtgen GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Advanced Proteome Therapeutics Corp (APC):企業の財務・戦略的SWOT分析
    Advanced Proteome Therapeutics Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • ABF Ingredients Ltd:戦略・SWOT・企業財務分析
    ABF Ingredients Ltd - Strategy, SWOT and Corporate Finance Report Summary ABF Ingredients Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Natcore Technology Inc (NXT):企業の財務・戦略的SWOT分析
    Summary Natcore Technology Inc (Natcore) is a solar research and development company that provides products for semiconductor and fiber optic applications. The company’s products include solar cell structures and black silicon cells. It uses liquid phase deposition technology for controlling deposit …
  • Blonder Tongue Laboratories, Inc. (BDR):企業の財務・戦略的SWOT分析
    Blonder Tongue Laboratories, Inc. (BDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Emlin Cosmetics :企業の戦略・SWOT・財務情報
    Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report Summary Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Tenaga Nasional Berhad (TENAGA):企業の財務・戦略的SWOT分析
    Tenaga Nasional Berhad (TENAGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Atrion Corp (ATRI):企業の財務・戦略的SWOT分析
    Atrion Corp (ATRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Targovax ASA (TRVX):企業の財務・戦略的SWOT分析
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG01, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipelin …
  • Brown-Forman Corporation:企業の戦略・SWOT・財務分析
    Brown-Forman Corporation - Strategy, SWOT and Corporate Finance Report Summary Brown-Forman Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • HeartWare International Inc:企業の戦略的SWOT分析
    HeartWare International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • EWE AG:石油・ガス:M&Aディール及び事業提携情報
    Summary EWE AG (EWE) operates in energy, telecommunication and information technology businesses. The company is involved in generation and transmission of energy, gas storage and waste water treatment. EWE plans, builds and operates renewable power generation plants globally. The company operates c …
  • Radico Khaitan Ltd.:企業の戦略・SWOT・財務分析
    Radico Khaitan Ltd. - Strategy, SWOT and Corporate Finance Report Summary Radico Khaitan Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Hycor Biomedical Inc-医療機器分野:企業M&A・提携分析
    Summary Hycor Biomedical Inc (Hycor) is a medical device company that manufactures and markets in-vitro diagnostic products. The company offers products such as auto immune testing systems, allergy testing systems, HYTEC plus and HYCOR ultrasensitive EIA products. Its auto immune testing products co …
  • Global Tungsten & Powders Corp.:企業の戦略・SWOT・財務情報
    Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report Summary Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Globo Comunicacao e Participacoes S.A.:企業の戦略的SWOT分析
    Globo Comunicacao e Participacoes S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • South African Express Airways (Pty) Ltd
    South African Express Airways (Pty) Ltd - Strategy, SWOT and Corporate Finance Report Summary South African Express Airways (Pty) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Dubai Electricity and Water Authority:企業の戦略的SWOT分析
    Dubai Electricity and Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆